By inhibiting pyroptosis to reduce neuroinflammation, PEG-bHb may prevent the development of secondary injury after traumatic brain injury
- Exp Neurol. 2025 Aug 27:115447. doi: 10.1016/j.expneurol.2025.115447.
- 1. Academy of Military Medical Sciences, 100850 Beijing, China.
- 2. Academy of Military Medical Sciences, 100850 Beijing, China; Department of Critical Care Neurosurgery, China Medical University Aviation General Hospital, 100012 Beijing, China.
- 3. Academy of Military Medical Sciences, 100850 Beijing, China. Electronic address: [email protected].
- 4. Academy of Military Medical Sciences, 100850 Beijing, China. Electronic address: [email protected].
- 5. Academy of Military Medical Sciences, 100850 Beijing, China. Electronic address: [email protected].
Changes in severe pathological microenvironment of traumatic brain injury (TBI) have important implications for neurological repair, including oxidative stress and intense neuroinflammatory responses. Pyroptosis, a regulated cellular demise process characterized by membrane permeabilization, constitutes a primary contributor to post-traumatic brain injury induced neural inflammatory responses. Regulating the Pyroptosis pathway may alleviate secondary brain injury. Polyethylene glycol-conjugated bovine Hemoglobin (PEG-bHb) is a type of hemoglobin-based oxygen carriers (HBOCs) and is designed for oxygen delivery in transfusion therapy. PEG-bHb exhibits the capacity to bind and release oxygen, promoting oxygen supply in hypoxic tissues. In vivo studies have found that PEG-bHb can elevate regional oxygen saturation after TBI in prehospital stage, effectively inhibit Pyroptosis, attenuate neuroinflammation and oxidative stress, and effectively attenuate the development of secondary brain injury. Furthermore, PEG-bHb has been demonstrated to protect the blood-brain barrier (BBB) by reducing the permeability of BBB and attenuating brain edema. PEG-bHb has been shown to enhance motor, learning, and memory abilities following TBI. Thus, PEG-bHb can act as a promising candidate for TBI treatment.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Biochemical Assay ReagentsResearch Areas: Cancer